Cargando…

Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are effective in preventing thromboembolisms and reduce the risk of bleeding compared with warfarin. There are few reports on the outcomes of on-label reduced-dose NOACs. The aim of this study was to assess the safety and efficacy of o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ju Youn, Choi, Eue Keun, Lim, Hong Euy, Oh, Yong-Seog, Cho, Youngjin, On, Young Keun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745682/ https://www.ncbi.nlm.nih.gov/pubmed/36513051 http://dx.doi.org/10.3346/jkms.2022.37.e335

Ejemplares similares

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
por: Choi, Eue-Keun, et al.
Publicado: (2021)

Virtual Ablation of Atrial Fibrillation in Patients With Persistent Atrial Fibrillation: An Unexplored Niche
por: Choi, Eue-Keun
Publicado: (2022)

Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients
por: Choi, Eue‐Keun, et al.
Publicado: (2023)

Lipidomic profiling reveals free fatty acid alterations in plasma from patients with atrial fibrillation
por: Jung, Youngae, et al.
Publicado: (2018)

A Genetic Risk Score for Atrial Fibrillation Predicts the Response to Catheter Ablation
por: Choe, Won-Seok, et al.
Publicado: (2018)

Cryoballoon Catheter Ablation in Korean Patients With Paroxysmal and Persistent Atrial Fibrillation: One Year Outcome From the Cryo Global Registry
por: Lim, Hong Euy, et al.
Publicado: (2022)

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

Effects of Low-Intensity Autonomic Nerve Stimulation on Atrial Electrophysiology
por: Cho, Youngjin, et al.
Publicado: (2014)

CORRIGENDUM: Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

A Paradigm Shift in Risk Prediction in Patients With Atrial Fibrillation
por: Choi, Eue-Keun, et al.
Publicado: (2022)

Angiotensin Receptor Blocker for Stroke Prevention in Atrial Fibrillation: beyond Blood Pressure Lowering?
por: Choi, Eue-Keun
Publicado: (2016)

Acute and long‐term efficacy of ablation index‐guided higher power shorter duration ablation in patients with atrial fibrillation: A prospective registry
por: Lee, So‐Ryoung, et al.
Publicado: (2021)

The difference of burden of ectopic beats in different types of atrial fibrillation and the effect of atrial fibrillation type on stroke risk in a prospective cohort of patients with atrial fibrillation (CODE-AF registry)
por: Cho, Seunghoon, et al.
Publicado: (2020)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Clinical Outcomes of Rhythm Control Strategies for Asymptomatic Atrial Fibrillation According to the Quality‐of‐Life Score: The CODE‐AF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) Registry
por: Kim, Ju Youn, et al.
Publicado: (2022)

Hemoptysis in Quadriplegia with Atrial Fibrillation Who Was Taking Edoxaban: a Case Report
por: Jeong, Hoyoung, et al.
Publicado: (2021)

2018 Korean Guideline of Atrial Fibrillation Management
por: Joung, Boyoung, et al.
Publicado: (2018)

Atrial Innervation Patterns of Intrinsic Cardiac Autonomic Nerves
por: Lee, So-Ryoung, et al.
Publicado: (2018)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022)

Coagulation Biomarkers for Predicting Clinical Outcomes Among Patients With Atrial Fibrillation: Piecing Together the Biomarkers
por: Choi, Eue-Keun, et al.
Publicado: (2023)

Protocol for LASER: A Randomized Evaluation and an Associated Registry of Early Anticoagulation With Edoxaban After Ischemic Stroke in Patients With Atrial Fibrillation
por: Alrohimi, Anas, et al.
Publicado: (2021)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Genome-wide association study-based prediction of atrial fibrillation using artificial intelligence
por: Kwon, Oh-Seok, et al.
Publicado: (2022)

Entrapment of a steerable diagnostic electrophysiologic catheter in the Thebesian valve during radiofrequency catheter ablation for atrial fibrillation
por: Lee, Euijae, et al.
Publicado: (2020)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
por: Diaz, Alejandro Bimbo, et al.
Publicado: (2023)

Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients
por: Li, Yan-Guang, et al.
Publicado: (2018)

Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study
por: Rhee, Tae-Min, et al.
Publicado: (2017)

Low Lipid Levels and High Variability are Associated With the Risk of New‐Onset Atrial Fibrillation
por: Lee, Hyun‐Jung, et al.
Publicado: (2019)

Impact of Hemoglobin Levels and Their Dynamic Changes on the Risk of Atrial Fibrillation: A Nationwide Population-Based Study
por: Lim, Woo-Hyun, et al.
Publicado: (2020)

Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial
por: Akashi, Shintaro, et al.
Publicado: (2022)

A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2022)

Prevalence of Non-valvular Atrial Fibrillation Based on Geographical Distribution and Socioeconomic Status in the Entire Korean Population
por: Lee, So-Ryoung, et al.
Publicado: (2018)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Rhythm Control and Cardiovascular or Cerebrovascular Outcomes in Patients with Atrial Fibrillation: A Study of the CODE-AF Registry
por: Chung, Ho-Gi, et al.
Publicado: (2023)

Machine Learning Prediction for the Recurrence After Electrical Cardioversion of Patients With Persistent Atrial Fibrillation
por: Kwon, Soonil, et al.
Publicado: (2023)

Type and Severity of Migraine Determines Risk of Atrial Fibrillation in Women
por: Rhee, Tae-Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7eoe3449j942o5smlbq7dasomk